> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Amyloid-targeting therapy eligibility in China narrowed by diagnosis and biomarker access
- URL: https://www.coios.me/amyloid-targeting-therapy-eligibility-in-china-narrowed-by/
- Published: 2026-11-19T13:02:10.000Z
- Updated: 2026-11-19T16:02:15.000Z
- Description: A meta-analysis estimated 39,825 Chinese adults eligible for amyloid-targeting therapy under current care, against 14.17 million without access constraints.
- Author: Daniel Ryan
- Tags: Health today, Dementia, China, #peer-reviewed, #new, #item, #source-2026-11, #score-62

This systematic review estimated MCI and AD prevalence and the population potentially eligible for amyloid-targeting therapy. It pooled population-based studies from 2020 to 2026, covering 312,204 participants aged 60 and over in mainland China. Pooled prevalence was 21.21% (95% CI 17.41–25.01%) for MCI and 4.72% (95% CI 3.13–6.31%) for AD. A stepwise funnel model then applied rates of consultation, clinical diagnosis, biomarker testing and amyloid positivity. Under current conditions, 39,825 people were potentially eligible for amyloid-targeting therapy, against 14.17 million without these constraints. Most studies were of moderate quality, heterogeneity was extreme (I² 99.7–99.8%), and age-stratified evidence was limited.

*Why it is interesting: The modelled eligible population falls from 14.17 million to 39,825 once current consultation, diagnosis and biomarker testing rates are applied. The gap places the main constraint on access in diagnostic pathways, not in disease prevalence.*

Source

[Advances in Therapy, 18 November 2026](https://doi.org/10.1007/s12325-026-03800-3?ref=coios.me)

DOI

10.1007/s12325-026-03800-3

Type

Peer-reviewed article

Design

Systematic review and random-effects meta-analysis of 27 population-based prevalence studies (n=312,204, adults 60+, searched 2020-Aug 2026) feeding a stepwise funnel model with probabilistic sensitivity analysis

Verdict

New finding

Driver

[Dementia](https://www.coios.me/d-dementia/)